Creating a medication tailored to the needs of an individual patient. FDA answers the “what” and “why” of compounding. From consumers to health care professionals, there are many questions about compounding. FDA works to answer questions related to the meaning, intent and requirements of compounding
Quick Take
The FDA has issued a comprehensive Q&A resource to clarify the definition, intent, and regulatory requirements of drug compounding for both healthcare providers and consumers. The guidance focuses on the process of creating medications tailored to the specific clinical needs of individual patients when FDA-approved products are not suitable.
Why It Matters
Compounding is a cornerstone of specialized eye care, particularly for myopia management, fortified antibiotics, and preservative-free formulations. However, the regulatory environment is complex, and clinicians often face uncertainty regarding the legal requirements and safety standards of compounded products. This FDA initiative provides a necessary framework for practitioners to better understand the 'what' and 'why' of compounding, helping to mitigate risks associated with sourcing non-standardized medications.
Key Details
Practice Implications
Eye care professionals should review these FDA clarifications to ensure their prescribing habits for custom formulations align with federal intent and requirements. When ordering compounded drops or ointments, practitioners must be able to justify the individual patient need that necessitates a tailored medication over a mass-produced, FDA-approved alternative.
Who's Affected
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.
